Richard A. Larson to Leukemia
This is a "connection" page, showing publications Richard A. Larson has written about Leukemia.
Connection Strength
1.886
-
Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3556s-63s.
Score: 0.239
-
Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002. Leukemia. 2003 Dec; 17(12):2358-82.
Score: 0.201
-
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 09 15; 140(11):1200-1228.
Score: 0.184
-
Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention. J Clin Oncol. 2022 11 10; 40(32):3709-3718.
Score: 0.181
-
Acute leukemia in adults: recent developments in diagnosis and treatment. CA Cancer J Clin. 1994 Nov-Dec; 44(6):326-52.
Score: 0.107
-
The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment. Ann N Y Acad Sci. 2014 Mar; 1310:7-31.
Score: 0.102
-
Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell. 2012 Oct 16; 22(4):524-35.
Score: 0.093
-
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs. 2008 Aug; 26(4):331-8.
Score: 0.068
-
Recurrent fungal pneumonias in patients with acute nonlymphocytic leukemia undergoing multiple courses of intensive chemotherapy. Am J Med. 1988 Feb; 84(2):233-9.
Score: 0.067
-
A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia. J Clin Oncol. 1987 Mar; 5(3):391-7.
Score: 0.063
-
End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood. 2007 Mar 01; 109(5):1810-6.
Score: 0.061
-
Gene expression profiles in acute myeloid leukemia with common translocations using SAGE. Proc Natl Acad Sci U S A. 2006 Jan 24; 103(4):1030-5.
Score: 0.058
-
Use of decline in D-xylose absorption to predict infection following intensive chemotherapy. Cancer Treat Rep. 1984 Dec; 68(12):1489-91.
Score: 0.054
-
The predictive value of initial cytogenetic studies in 148 adults with acute nonlymphocytic leukemia: a 12-year study (1970-1982). Cancer Genet Cytogenet. 1983 Nov; 10(3):219-36.
Score: 0.050
-
Chromosome changes in hematologic malignancies. CA Cancer J Clin. 1981 Jul-Aug; 31(4):222-38.
Score: 0.042
-
A follow-up study of synthetic rubber workers. Toxicology. 1996 Oct 28; 113(1-3):182-9.
Score: 0.031
-
Leukemia and cumulative exposure to butadiene, styrene and benzene among workers in the synthetic rubber industry. Toxicology. 1996 Oct 28; 113(1-3):190-202.
Score: 0.031
-
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs. 2013 Oct; 31(5):1311-20.
Score: 0.024
-
Therapy for acute myeloid leukemia and acute lymphoblastic leukemia in adults. Curr Opin Oncol. 1991 Feb; 3(1):30-8.
Score: 0.021
-
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma. 2009 Nov; 50(11):1809-17.
Score: 0.019
-
Low O6-alkylguanine DNA alkyltransferase activity in the peripheral blood lymphocytes of patients with therapy-related acute nonlymphocytic leukemia. Cancer Res. 1988 Jun 01; 48(11):3084-9.
Score: 0.017
-
Psychosocial symptomatology, personal growth, and development among young adult patients following the diagnosis of leukemia or lymphoma. J Clin Oncol. 1988 Apr; 6(4):613-7.
Score: 0.017
-
Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo. Leukemia. 1988 Feb; 2(2):79-83.
Score: 0.017
-
Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood. 1987 Nov; 70(5):1412-7.
Score: 0.016
-
High-performance liquid chromatographic assay for mitoxantrone in plasma using electrochemical detection. J Chromatogr. 1987 Sep 04; 420(1):81-8.
Score: 0.016
-
Assignment of CSF-1 to 5q33.1: evidence for clustering of genes regulating hematopoiesis and for their involvement in the deletion of the long arm of chromosome 5 in myeloid disorders. Proc Natl Acad Sci U S A. 1987 May; 84(9):2970-4.
Score: 0.016
-
High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup Study. J Clin Oncol. 1987 Jan; 5(1):75-82.
Score: 0.016
-
Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol. 1986 Mar; 4(3):325-45.
Score: 0.015
-
Assignment of the GM-CSF, CSF-1, and FMS genes to human chromosome 5 provides evidence for linkage of a family of genes regulating hematopoiesis and for their involvement in the deletion (5q) in myeloid disorders. Cold Spring Harb Symp Quant Biol. 1986; 51 Pt 2:899-909.
Score: 0.014
-
Limited efficacy of a four-day course of high-dose cytosine arabinoside in the treatment of poor-risk patients with acute nonlymphocytic leukemia. Cancer Chemother Pharmacol. 1986; 18(3):257-60.
Score: 0.014
-
Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia. Cancer. 1985 Aug 01; 56(3):443-9.
Score: 0.014
-
A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia. Leuk Lymphoma. 1992 Oct; 8(3):229-33.
Score: 0.006
-
Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation. Bone Marrow Transplant. 1992 Jan; 9(1):41-7.
Score: 0.005
-
Disseminated cutaneous and peritoneal hyalohyphomycosis caused by Fusarium species: three cases and review of the literature. Mycopathologia. 1988 Feb; 101(2):105-11.
Score: 0.004
-
Evidence for the involvement of GM-CSF and FMS in the deletion (5q) in myeloid disorders. Science. 1986 Feb 28; 231(4741):984-7.
Score: 0.004